大禹生物
(920970)
| 流通市值：4.77亿 | | | 总市值：7.55亿 |
| 流通股本：7007.13万 | | | 总股本：1.11亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 33,740,362.7 | 167,480,613.05 | 92,453,169.97 | 62,181,019.92 |
| 营业收入 | 33,740,362.7 | 167,480,613.05 | 92,453,169.97 | 62,181,019.92 |
| 二、营业总成本 | 38,871,433.38 | 199,734,100.78 | 105,747,869.62 | 72,339,105.57 |
| 营业成本 | 29,152,163.14 | 154,050,474.58 | 73,629,440.26 | 50,207,269.85 |
| 税金及附加 | 120,217.25 | 2,653,220.9 | 1,487,349.48 | 1,298,260.14 |
| 销售费用 | 2,682,092.82 | 12,982,821.89 | 9,065,103.54 | 6,234,706.53 |
| 管理费用 | 4,600,096.6 | 19,780,851.69 | 14,234,373.81 | 9,728,005.77 |
| 研发费用 | 1,264,383.24 | 6,800,764.61 | 5,012,359.78 | 3,493,526.07 |
| 财务费用 | 1,052,480.33 | 3,465,967.11 | 2,319,242.75 | 1,377,337.21 |
| 其中:利息费用 | 1,036,055.7 | 3,438,058.22 | 2,305,545.64 | 1,376,682.4 |
| 其中:利息收入 | 5,086.65 | 31,864.53 | 28,061.05 | 21,798.9 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | -2,360 | -2,360 | -2,360 |
| 加:投资收益 | - | 22,743.28 | 22,743.28 | 22,743.28 |
| 资产处置收益 | 27,337.6 | - | - | - |
| 资产减值损失(新) | -13,562,884.6 | -2,540,919.07 | -664,313.34 | -664,313.34 |
| 信用减值损失(新) | -339,765.88 | -859,716.69 | -964,951.53 | -894,346.79 |
| 其他收益 | 1,589,493.43 | 5,930,948.27 | 4,285,298.3 | 2,686,315.27 |
| 四、营业利润 | -17,416,890.13 | -29,702,791.94 | -10,618,282.94 | -9,010,047.23 |
| 加:营业外收入 | 253.24 | 420.07 | 1.31 | 1.29 |
| 减:营业外支出 | - | 121,438.04 | 96,736.48 | 11,489.28 |
| 五、利润总额 | -17,416,636.89 | -29,823,809.91 | -10,715,018.11 | -9,021,535.22 |
| 减:所得税费用 | - | 29,371.17 | 1,252.5 | 1,252.5 |
| 六、净利润 | -17,416,636.89 | -29,853,181.08 | -10,716,270.61 | -9,022,787.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -17,416,636.89 | -29,853,181.08 | -10,716,270.61 | -9,022,787.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -17,416,636.89 | -29,853,181.08 | -10,716,270.61 | -9,022,787.72 |
| 扣除非经常损益后的净利润 | -19,195,493.71 | -35,716,594.06 | -15,428,361.48 | -11,967,716.47 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.16 | -0.27 | -0.1 | -0.08 |
| (二)稀释每股收益 | -0.16 | -0.27 | -0.1 | -0.08 |
| 九、综合收益总额 | -17,416,636.89 | -29,853,181.08 | -10,716,270.61 | -9,022,787.72 |
| 归属于母公司股东的综合收益总额 | -17,416,636.89 | -29,853,181.08 | -10,716,270.61 | -9,022,787.72 |
| 公告日期 | 2026-04-27 | 2026-04-27 | 2025-10-27 | 2025-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |